Idarubicin including regimens in acute myelogenous leukemia in elderly patients

Critical Reviews in Oncology/Hematology

Volumn 32, Issue 1, 1999, Pages 59-68

  Leone, Giuseppe ^a   Sica, Simona ^a   Pagano, Livio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE DERIVATIVE; DAUNORUBICIN; ETOPOFOS; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; TIOGUANINE;

AGED; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GERIATRIC PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MYELOID LEUKEMIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0032846601     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00028-1     Document Type: Article

References (62)

1. Copplesome J.A., Prentice A.G. Acute myeloblastic leukemia in the elderly. Leuk. Res. 12:1988;617-625.
2. Hamblin T.J. Disappointments in treating acute leukemia in elderly. N. Engl. J. Med. 332:1995;1712-1713.
3. Taylor P.R., Reid M.M., Stark A.N. et al. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia. 9:1995;231-237.
4. Dombret H. Treatment of acute myeloid leukemia in the elderly. ISH-SHA Combined Congress Educational Program Book. In: Willemze R, McArthur JR, Kansu E, editors. Amsterdam, 1998. p. 108-113.
5. Burnett A.K., Eden O.B. The treatment of acute leukaemia. Lancet. 349:1997;270-275.
6. Keating A. The hematopoietic stem cell in elderly patients with leukemia. Leukemia. 10(suppl. 1):1996;S30-32.
7. Estey E., Thall P., Beran M. et al. Effect of diagnosis (refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 90:1997;2969-2977.
8. Schiffer C.A., Lee E.J., Tomiyasu T. et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia. Blood. 73:1989;263-270.
9. Leith C.P., Kopecky J., Godwin J. et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguieshes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 89:1997;3323-3329.
10. Willman C.L. Immunonophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of multidrug resistance gene-1 (MDR1). Leukemia. 10(suppl):1996;S33-35.
11. Rees J.K., Gray R.G., Swrsky D., Hayhoe F.G. Principal results of the Medical Research Councils 8th Acute Myeloid Leukaemia Trial. Lancet. 2:1986;1236-1242.
12. Yates J., Glidwell, Wiernik P. et al. Cytosine arabinoside with daunorubicin or adriamicin for therapy for acute myelocytic leukemia: a CALGB study. Blood. 60:1982;454-462.
13. Buchner T., Hiddeman W., Wormann B. et al. Daunorubicin 60 instead 30 mg/sqm improves response and survival in elderly patients with AML. Blood. 90(suppl. 1):1997;583a.
14. Dombret H., Chastang C., Fenaux P. et al. A controlled study of recombinant human granulocyte colony stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N. Engl. J. Med. 332:1995;1678-1683.
15. Heil G., Hoelzer D., Sanz M.A. et al. A randomized double blind placebo-controlled Phase III study of filgrastim in remission induction and consolidation therapy for adult with de novo acute myeloid leukemia. Blood. 90:1997;4710-4718.
16. Stone R.M., Berg D.T., George S.L. et al. Granulocyte macrophage colony stimulating factor after initial therapy for elderly patients with primary acute myelogenous leukemia. N. Engl. J. Med. 332:1995;1671-1677.
17. Lowenberg B., Suciu S., Archimbaud E. et al. Use of recombinant granulocyte macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11. A phase III randomized study of the EORTC-LCG and HOVON. Blood. 90:1997;2952-2961.
18. Witz F., Sadoun A., Perri M.C. et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony stimulating factor administered during and after induction treatment for the novo acute myelogenous leukemia in elderly patients. Blood. 91:1998;2722-2730.
19. Christoffersen P.S., Rasmussen K.K., Hermansen K. Cardiovascular effects of doxorubicin (adriamycin) and 4-demethoxydaunorubicin(idarubicin) in conscious rat. Pharmacol. Toxicol. 62:1998;54-56.
20. Anderlini P., Benjamin R.S., Wong F.C. et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 13:1995;2827-2834.
21. Curtis J.E., Minden M.D., Minkin S., McCulloch E.A. Sensitivities of AML blast stem cells to idarubicin: a comparison with normal hematopoietic progenitors. Leukemia. 9:1995;396-404.
22. Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in multidrug resistant leukemia cells. Blood. 79:1992;3267-3273.
23. Toffoli G., Corona G., Simone F. et al. Cellular pharmacology of idarubicinol in multidrug LoVo Cell lines. Int. J. Cancer. 67:1996;129-137.
24. Camaggi C.M., Strocchi E., Carisi P. et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother. Pharmacol. 30:1992;307-316.
25. Toffoli G., Sorio R., Aita P. et al. Pharmacology of chronic oral daily administration of idarubicin. Haematologica. 82(suppl. 5):1997;1-3.
26. Carella A.M., Santini G., Martinengo M. et al. A: 4-demethoxy-daunorubicin in refractory or relapsed acute leukemias. A pilot study. Cancer. 55:1985;1452-1454.
27. Berman E., Raymond V., Daghestani A. et al. 4-demethoxydaunorubicin (idarubicin) in combination with 1-D-arabinosycytosine in the treatment of relapsed or refractory leukemia. Cancer Res. 49:1989;477-481.
28. Leone G., Pagano L., Marra R. et al. Idarubicin with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia. Haematologica. 74:1989;57-61.
29. Carella A.M., Bergman E., Berman E. et al. Idarubicin in the treatment of acute leukemias, an overview of preclinical and clinical studies. Haematologica. 75:1990;159-169.
30. Carella A.M., Carlier P., Pungolino E. et al. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia. 7:1993;196-199.
31. Cassileth P.A., Harrington D.P., Appelbaum F.R. et al. Chemotherapy compared with autologous or allogenic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 339:1998;1649-1656.
32. Berman E., Heller G., Santorsa J. et al. Results of randomized trial comparing idarubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 77:1991;1666-1674.
33. Mandelli F., Petti M.C., Ardia A. et al. A randomized clinical trial comparing Idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. Eur. J. Cancer. 27:1991;750-755.
34. Vogler W.R., Velez-Garcia E., Weiner R.S. et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J. Clin. Oncol. 10:1992;1103-1111.
35. Wiernik P.H., Banks P.L.C., Case D.C. et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 79:1992;313-319.
36. Heyll A., Aul C., Ggolin F. et al. Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia. Ann. Hematol. 68:1994;279-283.
37. Invernizzi R., Pecci A., Rossi G. et al. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndrome. Haematologica. 82:1997;660-663.
38. Leoni F., Ciolli S., Giuliani G. et al. Attenuated-dose idarubicin in acute myeloid leukemia of the elderly: pharmacokinetic study and clinical results. Brit. J. Haematol. 90:1995;169-174.
39. Hernandez-Boluda J.C., Sierra J., Esteve J. et al. Treatment of elderly patients with AML: results of an individualized approach. Haematologica. 83:1998;34-39.
40. Estey E., Kantarjian H.M., O'Brien S. et al. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-T) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines. Mol. Ther. 1:1995;21-28.
41. Parker J.E., Pagliuca A., Mijovic A. et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukemia. Br. J. Haematol. 99:1997;939-944.
42. Avvisati G., ten Cate J.W., Mandelli F. Acute promyelocytic leukaemia. Brit. J. Haematol. 81:1992;315-320.
43. Avvisati G., Lo Coco F., Diviero D. et al. AIDA (all-trans retinoic acid+Idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malatttie Ematologiche Maligna dell'Adulto (GIMEMA) pilot study. Blood. 88:1996;1390-1398.
44. Latagliata R., Avvisati G., Lo Coco F. et al. The role of all-transretinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged>60. Ann. Oncol. 8:1997;1273-1275.
45. Reiffers J., Huguet F., Stoppa A.M. et al. A prospective randomized trial of idarubicin vs. daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia. 10:1996;389-395.
46. Pignon B., Witz F., Desablens B. et al. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The GOELAM group. Brit. J. Haematol. 94:1996;333-341.
47. Archimbaud E., Jehn U., Thomas X. et al. Idarubicin vs. mitoxantrone, in association to VP-16 and AraC for induction consolidation therapy followed by autologous stem cell transplantation in elderly patients with analysis of a randomized trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 16:1997;A7.
48. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Brit. J. Haematol. 103:1998;100-109.
49. Harouseeau J.L., Rigal-Huguet F., Hurteloup F. et al. Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as single agent. Eur. J. Hematol. 42:1989;182-185.
50. Pagano L., Sica S., Marra R. et al. Oral idarubicin plus cytarabinoside in the treatment of acute non-lymphoblastic leukemia in elderly patients. Haematologica. 76:1991;517-518.
51. Harousseau J.L., Huguet F., Reiffers J. et al. Oral idarubicin and low dose cytarabine as the initial treatment for acute myeloid leukemia in elderly patients. Leuk. Lymphoma. 1:1991;145-149.
52. Ruutu T., Almquist A., Hallman H. et al. Oral induction and consolidatiom of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia. 8:1994;11-15.
53. Jackson G.H., Taylor P.R., Iqbal A. et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukemia in the elderly: a report of toxicity and efficacy. Leukemia. 11:1997;1193-1196.
54. Montillo M. Preliminary results of a GIMEMA pilot study in the treatment of acute myeloid leukemia. Blood. 88(Suppl. 10):1996;218a.
55. Musso M., Porretto F., Crescimanno A. et al. Low dose long-term oral idarubicin in maintenance treatment of elderly acute myeloid leukemia. Haematologica. 82((5 suppl)):1997;4-8.
56. Lassus M, Rees JKH, Zurlo MG, Viaro DA. A multicenter phase II study of oral idarubicin in the treatment of acute myeloblastic leukemia in elderly patients. Final report. FICE internal report: 30/79933i (August 1993).
57. Malik S.T.A., Tucker J., Rohatiner A.Z.S. et al. Oral Idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia. Hematol. Oncol. 7:1989;423-427.
58. Lowenthal R.M., Lambertenghi-Deliliers G. Oral idarubicin as treatment for advanced myelodysplastic syndrome. Haematologica. 76:1991;398-401.
59. Keldsen N., Karle H., Hansen N.E., Nissen N.I. Oral idarubicin in elderly patients with acute myeloid leukemia. Eur. J. Haematol. 45:1990;60.
60. Helg C., Chapui B., Grob J.P., Pugin P. Acute myeloid leukemia with poor prognosis: treatment with oral idarubicin and low-dose cytarabine via subcutaneous route. Schweitz Med. Wochenschr. 120:1990;548-552.
61. Maslak P.G., Weiss M.A., Berman E. et al. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia. 10:1996;32-39.
62. Stewart D.J., Grewaal D., Green R.M. et al. Bioavailability and pharmacology of oral idarubicin. Cancer Chemother. Pharmacol. 27:1991;308-314.